Thomas Seck, MD, on the EMPA-REG OUTCOME Trial: Empagliflozin Reduces CV Risk by 38%


Thomas Seck, MD, vice president of Clinical Development and Medical Affairs – Primary Care at Boehringer Ingelheim Pharmaceuticals, Inc., spoke with us about the results of the landmark EMPA-REG OUTCOME Trial and what they mean for the treatment of diabetes and cardiovascular disease.

To read more about the EMPA-REG OUTCOME Trial, read our news brief here.

For more cardiology or diabetes content, visit our Medical Resource Centers.

Submit Feedback